DZP

NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY

Retrieved on: 
Thursday, April 11, 2024
FDA, American Academy, Brain, Seizure, DZP, Food, Research, Plasma, Patient, AAN, Physician, Epilepsy, Diazepam, Poster, SAN, Pharmaceutical industry

SAN DIEGO, April 11, 2024 /PRNewswire/ -- Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.  A second presentation will provide insight into characterization of a repeat-dosing model for preclinical diazepam studies. These findings will be showcased through posters at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.

Key Points: 
  • A second presentation will provide insight into characterization of a repeat-dosing model for preclinical diazepam studies.
  • These findings will be showcased through posters at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
  • "These studies represent our continued commitment to improving outcomes for patients with epilepsy," said Adrian L. Rabinowicz, M.D., Chief Medical Officer.
  • Sustained DZP levels were observed in plasma and brain, akin to human levels, suggesting potential long-acting effects.

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Retrieved on: 
Friday, December 1, 2023
Empowerment, Status epilepticus, Brain, Research, Annual general meeting, Additive effect, SAN, Food, American Epilepsy Society, Effectiveness, Panic, Literature, Plasma, Risk, Comparison, AAS, CIV, Diazepam, FDA, Prompt, Pharmacokinetics, Caregiver, Epilepsy, Human, DZP, Rat, Systematic review, AES, Pharmaceutical industry, Drug, Vaccine, Dietary supplement, Seizure, Male, Patient, Female, Safety

SAN DIEGO, Dec. 1, 2023 /PRNewswire/ -- Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023. Two of the presentations include new analyses of data from the completed long-term phase 3 open-label, repeat-dose safety study of diazepam nasal spray (VALTOCO®) for the treatment of seizure clusters in patients with epilepsy aged ≥6 years, evaluating timing, safety, and effectiveness of treatment. A third presentation focuses on the further assessment of diazepam in a novel preclinical model dosing strategy with potential application for further in vivo studies. Additional presentations explore the concept of anticipatory anxiety of seizures (AAS) through literature review, comparison of treated and untreated seizure clusters in a retrospective analysis from the SeizureTracker® database, and the short-term impact of seizures beyond the seizure itself.

Key Points: 
  • "Our ultimate goal is to improve health outcomes by addressing gaps in seizure cluster treatment and control," said Adrian L. Rabinowicz, M.D., Chief Medical Officer.
  • "The data presented this year at the AES annual meeting demonstrate our ongoing commitment to improving the future of epilepsy care by advancing meaningful, patient-focused treatment outcomes for people with epilepsy."
  • "Neurelis is at the forefront of epilepsy research, as evidenced by the wide breadth of data presented at this year's AES annual meeting," said Enrique Carrazana, M.D., Neurelis Senior Vice President, Strategic Initiatives.
  • Results showed sustained and measurable DZP levels in plasma and brain, which were similar to levels observed in humans.

Holmusk and Charité - Universitätsmedizin Berlin Enter a Strategic Collaboration to Drive Precision Psychiatry Using Novel Real-World Data

Retrieved on: 
Tuesday, November 23, 2021
Real-World Evidence, Patient, Natural language, Mental health, Psychiatry, Bed, RWD, Social, Partnership, Diagnosis, American Academy of Child and Adolescent Psychiatry, Real world data, Student, Crowned heads of Europe (phrase), Clinician, COVID-19, Department of Social and Preventive Medicine, University of Malaya, Data science, Nursing, Adolescence, Psychosomatic medicine, Research, The Pew Charitable Trusts, RWE, DZP, GDPR, Natural language processing, Preventive healthcare, Medical school, Neuroscience, German Centre for Integrative Biodiversity Research (iDiv), Department, Education, Dentistry, Pharmaceutical industry

The collaboration sets out to enable precision psychiatry for patients, by capturing and analysing real-world data.

Key Points: 
  • The collaboration sets out to enable precision psychiatry for patients, by capturing and analysing real-world data.
  • The strategic collaboration is focused on building multi-site, standardized real-world data capture infrastructure, including both clinician- and patient-reported assessments and outcomes.
  • Curated and digitized data will allow enhanced and real-time quality assessment and form the basis of measurement-based care in Germany.
  • This forward-thinking initiative is made possible by the partnership between Charit and Holmusk, a world leader in real-world data science in psychiatry.